# A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

> **NCT07712562** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Dren Bio** · enrollment: 60 (estimated)

## Conditions studied

- Bone Marrow Failure Syndromes
- Aplastic Anemias
- Severe Aplastic Anemia (SAA)
- Severe Aplastic Anemia, Relapse
- Severe Aplastic Anemia, Refractory
- Non-severe Aplastic Anemia

## Interventions

- **DRUG:** Dibotatug (DR-01)

## Key facts

- **NCT ID:** NCT07712562
- **Lead sponsor:** Dren Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-04
- **Final completion:** 2030-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712562, "A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*